Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

1.

Emerging technologies for assessing HER2 amplification.

Penault-Llorca F, Bilous M, Dowsett M, Hanna W, Osamura RY, Rüschoff J, van de Vijver M.

Am J Clin Pathol. 2009 Oct;132(4):539-48. doi: 10.1309/AJCPV2I0HGPMGBSQ. Review.

PMID:
19762531
[PubMed - indexed for MEDLINE]
Free Article
2.

[Assessment of HER2 status in breast cancer].

Penault-Llorca F, Cayre A.

Bull Cancer. 2004 Dec 1;91 Suppl 4:S211-5. Review. French.

PMID:
15899610
[PubMed - indexed for MEDLINE]
3.

[HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].

Akhdar A, Bronsard M, Lemieux R, Geha S.

Ann Pathol. 2011 Dec;31(6):472-9. doi: 10.1016/j.annpat.2011.10.013. Epub 2011 Nov 26. Review. French.

PMID:
22172120
[PubMed - indexed for MEDLINE]
4.

Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma.

Gruver AM, Peerwani Z, Tubbs RR.

J Clin Pathol. 2010 Mar;63(3):210-9. doi: 10.1136/jcp.2009.062760. Review.

PMID:
20203220
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

[HER2 gene amplification assay: is CISH an alternative to FISH?].

Denoux Y, Arnould L, Fiche M, Lannes B, Couturier J, Vincent-Salomon A, Penault-Llorca F, Antoine M, Balaton A, Baranzelli MC, Becette V, Bellocq JP, Bibeau F, Ettore F, Fridman V, Gnassia JP, Jacquemier J, MacGrogan G, Mathieu MC, Migeon C, Rigaud C, Roger P, Sigal-Zafrani B, Simony-Lafontaine J, Trassard M, Treilleux I, Verriele V, Voigt JJ; Groupe d'Etude des Facteurs Pronostiques en Immunohistochimie dans le Cancer du Sein.

Ann Pathol. 2003 Dec;23(6):617-22. Review. French.

PMID:
15094603
[PubMed - indexed for MEDLINE]
6.

Evaluation of HER2 status: for the treatment of metastatic breast cancers by humanized anti-HER2 Monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab).

Umemura S, Sakamoto G, Sasano H, Tsuda H, Akiyama F, Kurosumi M, Tokuda Y, Watanabe T, Toi M, Hasegawa T, Osamura RY.

Breast Cancer. 2001;8(4):316-20. Review.

PMID:
11791124
[PubMed - indexed for MEDLINE]
7.

Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy.

Ross JS.

Drug News Perspect. 2009 Mar;22(2):93-106. doi: 10.1358/dnp.2009.22.2.1334452. Review.

PMID:
19330168
[PubMed - indexed for MEDLINE]
8.

Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy.

Lee JA, Shaheen M, Walke T, Daly M.

Expert Rev Pharmacoecon Outcomes Res. 2011 Jun;11(3):325-41. doi: 10.1586/erp.11.25. Review.

PMID:
21671702
[PubMed - indexed for MEDLINE]
9.

Current status of HER2 testing.

Di Leo A, Dowsett M, Horten B, Penault-Llorca F.

Oncology. 2002;63 Suppl 1:25-32. Review.

PMID:
12422052
[PubMed - indexed for MEDLINE]
10.

Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy.

Chorn N.

Oncol Nurs Forum. 2006 Nov 3;33(2):265-72. Review.

PMID:
16518442
[PubMed - indexed for MEDLINE]
11.

HER2 status in breast cancer--an example of pharmacogenetic testing.

Kroese M, Zimmern RL, Pinder SE.

J R Soc Med. 2007 Jul;100(7):326-9. Review.

PMID:
17606754
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Recent trends of HER-2 testing and trastuzumab therapy for breast cancer.

Kurosumi M.

Breast Cancer. 2009;16(4):284-7. doi: 10.1007/s12282-009-0159-z. Epub 2009 Aug 6. Review.

PMID:
19657709
[PubMed - indexed for MEDLINE]
13.

Prospect for anti-her2 receptor therapy in breast cancer.

Brand FX, Ravanel N, Gauchez AS, Pasquier D, Payan R, Fagret D, Mousseau M.

Anticancer Res. 2006 Jan-Feb;26(1B):715-22. Review.

PMID:
16739343
[PubMed - indexed for MEDLINE]
Free Article
14.

[Human epidermal growth factor receptor 2 testing in breast cancer].

Ivković-Kapicl T, Knezević-Usaj S.

Med Pregl. 2010 Jan-Feb;63(1-2):69-74. Review. Serbian.

PMID:
20873313
[PubMed - indexed for MEDLINE]
15.

Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM).

Albanell J, Andreu X, Calasanz MJ, Concha A, Corominas JM, García-Caballero T, López JA, López-Ríos F, Ramón y Cajal S, Vera-Sempere FJ, Colomer R, Martín M, Alba E, González-Martín A, Llombart A, Lluch A, Palacios J.

Clin Transl Oncol. 2009 Jun;11(6):363-75. Review.

PMID:
19531451
[PubMed - indexed for MEDLINE]
16.

Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2).

van de Vijver MJ.

Eur J Cancer. 2001 Jan;37 Suppl 1:S11-7. Review.

PMID:
11167086
[PubMed - indexed for MEDLINE]
17.

HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools.

Hicks DG, Kulkarni S.

Am J Clin Pathol. 2008 Feb;129(2):263-73. doi: 10.1309/99AE032R9FM8WND1. Review.

PMID:
18208807
[PubMed - indexed for MEDLINE]
Free Article
18.

HER2 testing in the UK: further update to recommendations.

Walker RA, Bartlett JM, Dowsett M, Ellis IO, Hanby AM, Jasani B, Miller K, Pinder SE.

J Clin Pathol. 2008 Jul;61(7):818-24. doi: 10.1136/jcp.2007.054866. Epub 2008 Apr 1. Review.

PMID:
18381380
[PubMed - in process]
19.

HER2 testing in breast cancer: an overview of current techniques and recent developments.

Pathmanathan N, Bilous AM.

Pathology. 2012 Dec;44(7):587-95. doi: 10.1097/PAT.0b013e328359cf9a. Review.

PMID:
23111474
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk